drugset / Trial / NCT03400163
A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)
Timeline
- Start
- 2015-05-08
- Primary completion
- 2017-01-18
- Completion
- 2017-06-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegbelfermin | Protein / enzyme biologic | 20 mg | — |